Predictive factors of response to peginterferon and ribavirin in tunisians patients with chronic hepatitis c: about 141 cases
Keywords:
chronic hepatitis c, Treatment, Peg interferon, PrognosisAbstract
Background: The current treatment recommendation for chronic hepatitis c is the combination of peginterferon and ribavirin.aims: To report our experience in the treatment of chronic hepatitis c and determine the predictive factors of sustained virologic response.
methods: Analysis of consecutive patients treated with peginterferon and ribavirine from 1st January 2000 and 31st December 2009.
results: 141 patients with an average age of 50 years were included. 75 % of the patients were infected by a VHc of genotype 1. 22.6 % of the patients were cirrhotics. 7 % of the patients (n=10) had to stop the treatment because of severe side-effects. A reduction of the dose was indicated for 16 % of the patients (n=23). Among the 117 patients with the end of treatment virologic response, 24 patients (20.5%) relapse during the 6 months after the end of therapy. The sustained virologic response in intention to treat was 66 % (57.9 % in case of genotype 1-4 and 91 % in case of genotype 2-3). In multivariate analysis, 4 independent factors of sustained virologic response were identified: the male gender, a viral genotype not 1, a pre-therapeutic viral load ≤ 600 000 UI / ml and a rapid virologic response.
Conclusion: Approximately two thirds of the patients with chronic hepatitis c achieved a sustained virologic response with peginterferon and ribavirin. Our results are comparable to those of the literature. They will credibly be improved by the introduction of the new antiviral agents.
Downloads
References
Shepard cW, Finelli L, Alter MJ. Global epidemiology of hepatitis c virus infection. Lancet Infect Dis 2005;5:558-67.
Bronowicki JP, Barraud H, Peyrin-Biroulet L. Epidemiology and natural history of hepatitis c. Rev Prat 2005;55:607-14
Manns MP, McHutchison JG, Gordon Sc, et al. Peginterferon alfa- 2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis c: a randomised trial. Lancet 2001;358:958-65.
Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alfa- 2a and ribavirin combination therapy in chronic hepatitis c: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
Marcellin P. Hepatitis c: The recovery. Gastroenterol clin Biol 2009;33:819-29.
Sporea I, Sirli R, curescu M, et al. Outcome of antiviral treatment in patients with chronic genotype 1 HcV hepatitis. A retrospective study in 507 patients. J Gastrointestin Liver Dis 2010;19:261-4.
Belhadj N, Houissa F, Elloumi H, et al. Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis c: a preliminary study. Tunis Med 2008;86:341-5.
Goh PG, Kim MJ, Kim HJ, et al. Importance of medication adherence to peginterferon-ribavirin combination therapy in patients with chronic hepatitis c. Korean J Gastroenterol 2011;57:294-301.
Liu cH, Liu cJ, Lin cL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis c virus genotype 1 infection: a multicenter randomized controlled trial. clin Infect Dis 2008;47:1260-9.
Pattullo V, Heathcote JE, Wong DK. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis c. Hepatol Int 2010;4:723-31.
Tsubota A, Fujise K, Namiki Y, Tada N. Peginterferon and ribavirin treatment for hepatitis c virus infection. World J Gastroenterol 2011;17:419-32.
Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis c. J Hepatol 2005;43:250-7.
McHutchison JG, Lawitz EJ, Shiffman ML, et al. For the IDEAL study team peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis c infection. N Engl J Med 2009;361:580- 93.
Martinot-Peignoux M, Maylin S, Moucari R, et al. Virological response at 4 weeks to predict outcome of hepatitis c treatment with peginterferon and ribavirin. Antivir Ther 2009;13:701-7.
Hezode c. Traitement sur mesure du génotype 1.Hépato-Gastro 2008;15:7-10.
Ghany MG, Strader DB, Thomas DL, Seeff LB. AASLD practice guidelines: diagnosis, management, and treatment of hepatitis c: an update. Hepatology 2009;29:1335-74
EASL clinical Practice Guidelines: Management of hepatitis c virus infection. J Hepatol 2011;55:245-64.
D'Heygere F, George c, Van Vlierberghe H, et al. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis c infected with genotype 5: a meta-analysis of two large prospective clinical trials. J Med Virol 2011;83:815-9.
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis c treatment-induced viral clearance. Nature 2009;461:399-401.
M. Bourlière, D. Ouzan, M. Rosenheim, et al. Traitement de l'hépatite chronique c par Peginterferon alfa 2a et ribavirine en milieu hospitalier et libéral : résultats des 2101 malades inclus dans l'étude Hepatys. Gastroenterol clin Biol 2007;31:40.
Patton HM, Patel K, Behling c, et al. The impact of steatosis on disease progression and early sustained treatment response in chronic hepatitis c patients. J hepatol 2004;40:484-90.
Bruno S, cammà c, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis c: a randomized controlled trial. J Hepatol 2004;41:474-81.
Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HcV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
Kwo PY, Lawitz EJ, Mccone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis c infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2011;376:705-16.
McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HcV infection. N Engl J Med 2010;362:1292-303.
